APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Aminoglycosides Antibiotics Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Aminoglycosides Antibiotics Drug Market Analysis and Forecast 2026-2032

Report ID 17396284022 January 2026197 pages

Choose your research edition.

Industry ResearchAminoglycosides Antibiotics Drug Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Aminoglycosides Antibiotics Drug Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Aminoglycosides Antibiotics Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Aminoglycosides Antibiotics Drug Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Aminoglycosides Antibiotics Drug Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Aminoglycosides Antibiotics Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Aminoglycosides Antibiotics Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Aminoglycosides Antibiotics Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Aminoglycosides Antibiotics Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Aminoglycosides Antibiotics Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Aminoglycosides Antibiotics Drug include Teva, Novartis, Pfizer, Fresenius Kabi, Sun Pharma, Lannett Company, Jemicare, Hikma and Fangyuan-pharma, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Aminoglycosides Antibiotics Drug, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Aminoglycosides Antibiotics Drug, also provides the revenue of main regions and countries. Of the upcoming market potential for Aminoglycosides Antibiotics Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Aminoglycosides Antibiotics Drug revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Aminoglycosides Antibiotics Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Aminoglycosides Antibiotics Drug revenue, projected growth trends, production technology, application and end-user industry.

Aminoglycosides Antibiotics Drug Segment by Company

Teva

Novartis

Pfizer

Fresenius Kabi

Sun Pharma

Lannett Company

Jemicare

Hikma

Fangyuan-pharma

Cipla

Aike Pharmaceutical

Aminoglycosides Antibiotics Drug Segment by Type

Etimicin

Neomycin

Tobramycin

Gentamicin

Amikacin

Others

Aminoglycosides Antibiotics Drug Segment by Application

Hospital

Clinic

Others

Aminoglycosides Antibiotics Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Aminoglycosides Antibiotics Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Aminoglycosides Antibiotics Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Aminoglycosides Antibiotics Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Aminoglycosides Antibiotics Drug in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Aminoglycosides Antibiotics Drug company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Aminoglycosides Antibiotics Drug revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Aminoglycosides Antibiotics Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Etimicin Major Player Table 3. Neomycin Major Player Table 4. Tobramycin Major Player Table 5. Gentamicin Major Player Table 6. Amikacin Major Player Table 7. Others Major Player Table 8. Global Aminoglycosides Antibiotics Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Major Player Table 10. Clinic Major Player Table 11. Others Major Player Table 12. Aminoglycosides Antibiotics Drug Industry Trends Table 13. Aminoglycosides Antibiotics Drug Industry Drivers Table 14. Aminoglycosides Antibiotics Drug Industry Opportunities and Challenges Table 15. Aminoglycosides Antibiotics Drug Industry Restraints Table 16. Global Aminoglycosides Antibiotics Drug Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 17. Global Aminoglycosides Antibiotics Drug Market Size by Region (2021-2026) & (US$ Million) Table 18. Global Aminoglycosides Antibiotics Drug Market Share by Region (2021-2026) Table 19. Global Aminoglycosides Antibiotics Drug Market Size by Region (2027-2032) & (US$ Million) Table 20. Global Aminoglycosides Antibiotics Drug Market Share by Region (2027-2032) Table 21. Global Aminoglycosides Antibiotics Drug Revenue by Players (US$ Million) & (2021-2026) Table 22. Global Aminoglycosides Antibiotics Drug Revenue Market Share by Players (2021-2026) Table 23. Global Aminoglycosides Antibiotics Drug Key Players Ranking, 2024 VS 2025 VS 2026 Table 24. Global Aminoglycosides Antibiotics Drug Key Players Headquarters & Area Served Table 25. Global Aminoglycosides Antibiotics Drug Players, Product Type & Application Table 26. Global Aminoglycosides Antibiotics Drug Players Establishment Date Table 27. Global Players Market Concentration Ratio (CR5 and HHI) Table 28. Global Aminoglycosides Antibiotics Drug by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 29. Global Aminoglycosides Antibiotics Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Aminoglycosides Antibiotics Drug Revenue by Type (2021-2026) & (US$ Million) Table 31. Global Aminoglycosides Antibiotics Drug Revenue by Type (2027-2032) & (US$ Million) Table 32. Global Aminoglycosides Antibiotics Drug Revenue Market Share by Type (2021-2026) Table 33. Global Aminoglycosides Antibiotics Drug Revenue Market Share by Type (2027-2032) Table 34. Global Aminoglycosides Antibiotics Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Aminoglycosides Antibiotics Drug Revenue by Application (2021-2026) & (US$ Million) Table 36. Global Aminoglycosides Antibiotics Drug Revenue by Application (2027-2032) & (US$ Million) Table 37. Global Aminoglycosides Antibiotics Drug Revenue Market Share by Application (2021-2026) Table 38. Global Aminoglycosides Antibiotics Drug Revenue Market Share by Application (2027-2032) Table 39. Teva Company Information Table 40. Teva Business Overview Table 41. Teva Aminoglycosides Antibiotics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Teva Aminoglycosides Antibiotics Drug Product Portfolio Table 43. Teva Recent Development Table 44. Novartis Company Information Table 45. Novartis Business Overview Table 46. Novartis Aminoglycosides Antibiotics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Novartis Aminoglycosides Antibiotics Drug Product Portfolio Table 48. Novartis Recent Development Table 49. Pfizer Company Information Table 50. Pfizer Business Overview Table 51. Pfizer Aminoglycosides Antibiotics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Pfizer Aminoglycosides Antibiotics Drug Product Portfolio Table 53. Pfizer Recent Development Table 54. Fresenius Kabi Company Information Table 55. Fresenius Kabi Business Overview Table 56. Fresenius Kabi Aminoglycosides Antibiotics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. Fresenius Kabi Aminoglycosides Antibiotics Drug Product Portfolio Table 58. Fresenius Kabi Recent Development Table 59. Sun Pharma Company Information Table 60. Sun Pharma Business Overview Table 61. Sun Pharma Aminoglycosides Antibiotics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Sun Pharma Aminoglycosides Antibiotics Drug Product Portfolio Table 63. Sun Pharma Recent Development Table 64. Lannett Company Company Information Table 65. Lannett Company Business Overview Table 66. Lannett Company Aminoglycosides Antibiotics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Lannett Company Aminoglycosides Antibiotics Drug Product Portfolio Table 68. Lannett Company Recent Development Table 69. Jemicare Company Information Table 70. Jemicare Business Overview Table 71. Jemicare Aminoglycosides Antibiotics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Jemicare Aminoglycosides Antibiotics Drug Product Portfolio Table 73. Jemicare Recent Development Table 74. Hikma Company Information Table 75. Hikma Business Overview Table 76. Hikma Aminoglycosides Antibiotics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Hikma Aminoglycosides Antibiotics Drug Product Portfolio Table 78. Hikma Recent Development Table 79. Fangyuan-pharma Company Information Table 80. Fangyuan-pharma Business Overview Table 81. Fangyuan-pharma Aminoglycosides Antibiotics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. Fangyuan-pharma Aminoglycosides Antibiotics Drug Product Portfolio Table 83. Fangyuan-pharma Recent Development Table 84. Cipla Company Information Table 85. Cipla Business Overview Table 86. Cipla Aminoglycosides Antibiotics Drug Revenue and Gross Margin (US$ Million) & (2021-2026) Table 87. Cipla Aminoglycosides Antibiotics Drug Product Portfolio Table 88. Cipla Recent Development Table 89. Aike Pharmaceutical Company Information Table 90. Aike Pharmaceutical Business Overview Table 91. Aike Pharmaceutical Aminoglycosides Antibiotics Drug Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Aike Pharmaceutical Aminoglycosides Antibiotics Drug Product Portfolio Table 93. Aike Pharmaceutical Recent Development Table 94. North America Aminoglycosides Antibiotics Drug Revenue by Type (2021-2026) & (US$ Million) Table 95. North America Aminoglycosides Antibiotics Drug Revenue by Type (2027-2032) & (US$ Million) Table 96. North America Aminoglycosides Antibiotics Drug Revenue by Application (2021-2026) & (US$ Million) Table 97. North America Aminoglycosides Antibiotics Drug Revenue by Application (2027-2032) & (US$ Million) Table 98. North America Aminoglycosides Antibiotics Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 99. North America Aminoglycosides Antibiotics Drug Revenue by Country (2021-2026) & (US$ Million) Table 100. North America Aminoglycosides Antibiotics Drug Revenue by Country (US$ Million) & (2027-2032) Table 101. Europe Aminoglycosides Antibiotics Drug Revenue by Type (2021-2026) & (US$ Million) Table 102. Europe Aminoglycosides Antibiotics Drug Revenue by Type (2027-2032) & (US$ Million) Table 103. Europe Aminoglycosides Antibiotics Drug Revenue by Application (2021-2026) & (US$ Million) Table 104. Europe Aminoglycosides Antibiotics Drug Revenue by Application (2027-2032) & (US$ Million) Table 105. Europe Aminoglycosides Antibiotics Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. Europe Aminoglycosides Antibiotics Drug Revenue by Country (2021-2026) & (US$ Million) Table 107. Europe Aminoglycosides Antibiotics Drug Revenue by Country (US$ Million) & (2027-2032) Table 108. China Aminoglycosides Antibiotics Drug Revenue by Type (2021-2026) & (US$ Million) Table 109. China Aminoglycosides Antibiotics Drug Revenue by Type (2027-2032) & (US$ Million) Table 110. China Aminoglycosides Antibiotics Drug Revenue by Application (2021-2026) & (US$ Million) Table 111. China Aminoglycosides Antibiotics Drug Revenue by Application (2027-2032) & (US$ Million) Table 112. Asia Aminoglycosides Antibiotics Drug Revenue by Type (2021-2026) & (US$ Million) Table 113. Asia Aminoglycosides Antibiotics Drug Revenue by Type (2027-2032) & (US$ Million) Table 114. Asia Aminoglycosides Antibiotics Drug Revenue by Application (2021-2026) & (US$ Million) Table 115. Asia Aminoglycosides Antibiotics Drug Revenue by Application (2027-2032) & (US$ Million) Table 116. Asia Aminoglycosides Antibiotics Drug Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 117. Asia Aminoglycosides Antibiotics Drug Revenue by Region (US$ Million) & (2021-2026) Table 118. Asia Aminoglycosides Antibiotics Drug Revenue by Region (US$ Million) & (2027-2032) Table 119. SAMEA Aminoglycosides Antibiotics Drug Revenue by Type (2021-2026) & (US$ Million) Table 120. SAMEA Aminoglycosides Antibiotics Drug Revenue by Type (2027-2032) & (US$ Million) Table 121. SAMEA Aminoglycosides Antibiotics Drug Revenue by Application (2021-2026) & (US$ Million) Table 122. SAMEA Aminoglycosides Antibiotics Drug Revenue by Application (2027-2032) & (US$ Million) Table 123. SAMEA Aminoglycosides Antibiotics Drug Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 124. SAMEA Aminoglycosides Antibiotics Drug Revenue by Country (2021-2026) & (US$ Million) Table 125. SAMEA Aminoglycosides Antibiotics Drug Revenue by Country (US$ Million) & (2027-2032) Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Aminoglycosides Antibiotics Drug Image Figure 2. Global Aminoglycosides Antibiotics Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Aminoglycosides Antibiotics Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. Etimicin Image Figure 5. Neomycin Image Figure 6. Tobramycin Image Figure 7. Gentamicin Image Figure 8. Amikacin Image Figure 9. Others Image Figure 10. Global Aminoglycosides Antibiotics Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Aminoglycosides Antibiotics Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Aminoglycosides Antibiotics Drug Market Size (US$ Million) & (2021-2032) Figure 16. Global Aminoglycosides Antibiotics Drug Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 17. Global Aminoglycosides Antibiotics Drug Market Share by Region: 2021 VS 2025 VS 2032 Figure 18. Global Aminoglycosides Antibiotics Drug Players Revenue Share Top 10 and Top 5 in 2025 Figure 19. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 20. Global Aminoglycosides Antibiotics Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Aminoglycosides Antibiotics Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 22. Global Aminoglycosides Antibiotics Drug Revenue Market Share by Type (2021-2032) Figure 23. Global Aminoglycosides Antibiotics Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Aminoglycosides Antibiotics Drug Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 25. Global Aminoglycosides Antibiotics Drug Revenue Market Share by Application (2021-2032) Figure 26. North America Aminoglycosides Antibiotics Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 27. North America Aminoglycosides Antibiotics Drug Revenue Share by Type (2021-2032) Figure 28. North America Aminoglycosides Antibiotics Drug Revenue Share by Application (2021-2032) Figure 29. North America Aminoglycosides Antibiotics Drug Revenue Share by Country (2021-2032) Figure 30. United States Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Canada Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Mexico Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. Europe Aminoglycosides Antibiotics Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 34. Europe Aminoglycosides Antibiotics Drug Revenue Share by Type (2021-2032) Figure 35. Europe Aminoglycosides Antibiotics Drug Revenue Share by Application (2021-2032) Figure 36. Europe Aminoglycosides Antibiotics Drug Revenue Share by Country (2021-2032) Figure 37. Germany Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. France Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. U.K. Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Italy Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Spain Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Russia Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Netherlands Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. Nordic Countries Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 45. China Aminoglycosides Antibiotics Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. China Aminoglycosides Antibiotics Drug Revenue Share by Type (2021-2032) Figure 47. China Aminoglycosides Antibiotics Drug Revenue Share by Application (2021-2032) Figure 48. Asia Aminoglycosides Antibiotics Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 49. Asia Aminoglycosides Antibiotics Drug Revenue Share by Type (2021-2032) Figure 50. Asia Aminoglycosides Antibiotics Drug Revenue Share by Application (2021-2032) Figure 51. Asia Aminoglycosides Antibiotics Drug Revenue Share by Region (2021-2032) Figure 52. Japan Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. South Korea Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. India Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Australia Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Taiwan Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. Southeast Asia Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. SAMEA Aminoglycosides Antibiotics Drug Revenue YoY Growth (2021-2032) & (US$ Million) Figure 59. SAMEA Aminoglycosides Antibiotics Drug Revenue Share by Type (2021-2032) Figure 60. SAMEA Aminoglycosides Antibiotics Drug Revenue Share by Application (2021-2032) Figure 61. SAMEA Aminoglycosides Antibiotics Drug Revenue Share by Country (2021-2032) Figure 62. Brazil Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Argentina Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Chile Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Colombia Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Peru Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Saudi Arabia Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Israel Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. UAE Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Turkey Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Iran Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Egypt Aminoglycosides Antibiotics Drug Revenue YoY Growth (US$ Million) & (2021-2032) Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Etimicin
  • Neomycin
  • Tobramycin
  • Gentamicin
  • Amikacin
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Teva
  • Novartis
  • Pfizer
  • Fresenius Kabi
  • Sun Pharma
  • Lannett Company
  • Jemicare
  • Hikma
  • Fangyuan-pharma
  • Cipla
  • Aike Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Aminoglycosides Antibiotics Drug Market by Type
  3. 1.2.1 Global Aminoglycosides Antibiotics Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Etimicin
  5. 1.2.3 Neomycin
  6. 1.2.4 Tobramycin
  7. 1.2.5 Gentamicin
  8. 1.2.6 Amikacin
  9. 1.2.7 Others
  10. 1.3 Aminoglycosides Antibiotics Drug Market by Application
  11. 1.3.1 Global Aminoglycosides Antibiotics Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital
  13. 1.3.3 Clinic
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Aminoglycosides Antibiotics Drug Market Dynamics
  1. 2.1 Aminoglycosides Antibiotics Drug Industry Trends
  2. 2.2 Aminoglycosides Antibiotics Drug Industry Drivers
  3. 2.3 Aminoglycosides Antibiotics Drug Industry Opportunities and Challenges
  4. 2.4 Aminoglycosides Antibiotics Drug Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Aminoglycosides Antibiotics Drug Market Perspective (2021-2032)
  2. 3.2 Global Aminoglycosides Antibiotics Drug Growth Trends by Region
  3. 3.2.1 Global Aminoglycosides Antibiotics Drug Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Aminoglycosides Antibiotics Drug Market Size by Region (2021-2026)
  5. 3.2.3 Global Aminoglycosides Antibiotics Drug Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Aminoglycosides Antibiotics Drug Revenue by Players
  2. 4.1.1 Global Aminoglycosides Antibiotics Drug Revenue by Players (2021-2026)
  3. 4.1.2 Global Aminoglycosides Antibiotics Drug Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Aminoglycosides Antibiotics Drug Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Aminoglycosides Antibiotics Drug Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Aminoglycosides Antibiotics Drug Key Players Headquarters & Area Served
  7. 4.4 Global Aminoglycosides Antibiotics Drug Players, Product Type & Application
  8. 4.5 Global Aminoglycosides Antibiotics Drug Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Aminoglycosides Antibiotics Drug Market CR5 and HHI
  11. 4.6.3 2025 Aminoglycosides Antibiotics Drug Tier 1, Tier 2, and Tier 3
5 Aminoglycosides Antibiotics Drug Market Size by Type
  1. 5.1 Global Aminoglycosides Antibiotics Drug Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Aminoglycosides Antibiotics Drug Revenue by Type (2021-2032)
  3. 5.3 Global Aminoglycosides Antibiotics Drug Revenue Market Share by Type (2021-2032)
6 Aminoglycosides Antibiotics Drug Market Size by Application
  1. 6.1 Global Aminoglycosides Antibiotics Drug Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Aminoglycosides Antibiotics Drug Revenue by Application (2021-2032)
  3. 6.3 Global Aminoglycosides Antibiotics Drug Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Teva
  2. 7.1.1 Teva Company Information
  3. 7.1.2 Teva Business Overview
  4. 7.1.3 Teva Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Teva Aminoglycosides Antibiotics Drug Product Portfolio
  6. 7.1.5 Teva Recent Developments
  7. 7.2 Novartis
  8. 7.2.1 Novartis Company Information
  9. 7.2.2 Novartis Business Overview
  10. 7.2.3 Novartis Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Novartis Aminoglycosides Antibiotics Drug Product Portfolio
  12. 7.2.5 Novartis Recent Developments
  13. 7.3 Pfizer
  14. 7.3.1 Pfizer Company Information
  15. 7.3.2 Pfizer Business Overview
  16. 7.3.3 Pfizer Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Pfizer Aminoglycosides Antibiotics Drug Product Portfolio
  18. 7.3.5 Pfizer Recent Developments
  19. 7.4 Fresenius Kabi
  20. 7.4.1 Fresenius Kabi Company Information
  21. 7.4.2 Fresenius Kabi Business Overview
  22. 7.4.3 Fresenius Kabi Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Fresenius Kabi Aminoglycosides Antibiotics Drug Product Portfolio
  24. 7.4.5 Fresenius Kabi Recent Developments
  25. 7.5 Sun Pharma
  26. 7.5.1 Sun Pharma Company Information
  27. 7.5.2 Sun Pharma Business Overview
  28. 7.5.3 Sun Pharma Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sun Pharma Aminoglycosides Antibiotics Drug Product Portfolio
  30. 7.5.5 Sun Pharma Recent Developments
  31. 7.6 Lannett Company
  32. 7.6.1 Lannett Company Company Information
  33. 7.6.2 Lannett Company Business Overview
  34. 7.6.3 Lannett Company Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Lannett Company Aminoglycosides Antibiotics Drug Product Portfolio
  36. 7.6.5 Lannett Company Recent Developments
  37. 7.7 Jemicare
  38. 7.7.1 Jemicare Company Information
  39. 7.7.2 Jemicare Business Overview
  40. 7.7.3 Jemicare Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Jemicare Aminoglycosides Antibiotics Drug Product Portfolio
  42. 7.7.5 Jemicare Recent Developments
  43. 7.8 Hikma
  44. 7.8.1 Hikma Company Information
  45. 7.8.2 Hikma Business Overview
  46. 7.8.3 Hikma Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Hikma Aminoglycosides Antibiotics Drug Product Portfolio
  48. 7.8.5 Hikma Recent Developments
  49. 7.9 Fangyuan-pharma
  50. 7.9.1 Fangyuan-pharma Company Information
  51. 7.9.2 Fangyuan-pharma Business Overview
  52. 7.9.3 Fangyuan-pharma Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Fangyuan-pharma Aminoglycosides Antibiotics Drug Product Portfolio
  54. 7.9.5 Fangyuan-pharma Recent Developments
  55. 7.10 Cipla
  56. 7.10.1 Cipla Company Information
  57. 7.10.2 Cipla Business Overview
  58. 7.10.3 Cipla Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Cipla Aminoglycosides Antibiotics Drug Product Portfolio
  60. 7.10.5 Cipla Recent Developments
  61. 7.11 Aike Pharmaceutical
  62. 7.11.1 Aike Pharmaceutical Company Information
  63. 7.11.2 Aike Pharmaceutical Business Overview
  64. 7.11.3 Aike Pharmaceutical Aminoglycosides Antibiotics Drug Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Aike Pharmaceutical Aminoglycosides Antibiotics Drug Product Portfolio
  66. 7.11.5 Aike Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Aminoglycosides Antibiotics Drug Revenue (2021-2032)
  2. 8.2 North America Aminoglycosides Antibiotics Drug Revenue by Type (2021-2032)
  3. 8.2.1 North America Aminoglycosides Antibiotics Drug Revenue by Type (2021-2026)
  4. 8.2.2 North America Aminoglycosides Antibiotics Drug Revenue by Type (2027-2032)
  5. 8.3 North America Aminoglycosides Antibiotics Drug Revenue Share by Type (2021-2032)
  6. 8.4 North America Aminoglycosides Antibiotics Drug Revenue by Application (2021-2032)
  7. 8.4.1 North America Aminoglycosides Antibiotics Drug Revenue by Application (2021-2026)
  8. 8.4.2 North America Aminoglycosides Antibiotics Drug Revenue by Application (2027-2032)
  9. 8.5 North America Aminoglycosides Antibiotics Drug Revenue Share by Application (2021-2032)
  10. 8.6 North America Aminoglycosides Antibiotics Drug Revenue by Country
  11. 8.6.1 North America Aminoglycosides Antibiotics Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Aminoglycosides Antibiotics Drug Revenue by Country (2021-2026)
  13. 8.6.3 North America Aminoglycosides Antibiotics Drug Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Aminoglycosides Antibiotics Drug Revenue (2021-2032)
  2. 9.2 Europe Aminoglycosides Antibiotics Drug Revenue by Type (2021-2032)
  3. 9.2.1 Europe Aminoglycosides Antibiotics Drug Revenue by Type (2021-2026)
  4. 9.2.2 Europe Aminoglycosides Antibiotics Drug Revenue by Type (2027-2032)
  5. 9.3 Europe Aminoglycosides Antibiotics Drug Revenue Share by Type (2021-2032)
  6. 9.4 Europe Aminoglycosides Antibiotics Drug Revenue by Application (2021-2032)
  7. 9.4.1 Europe Aminoglycosides Antibiotics Drug Revenue by Application (2021-2026)
  8. 9.4.2 Europe Aminoglycosides Antibiotics Drug Revenue by Application (2027-2032)
  9. 9.5 Europe Aminoglycosides Antibiotics Drug Revenue Share by Application (2021-2032)
  10. 9.6 Europe Aminoglycosides Antibiotics Drug Revenue by Country
  11. 9.6.1 Europe Aminoglycosides Antibiotics Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Aminoglycosides Antibiotics Drug Revenue by Country (2021-2026)
  13. 9.6.3 Europe Aminoglycosides Antibiotics Drug Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Aminoglycosides Antibiotics Drug Revenue (2021-2032)
  2. 10.2 China Aminoglycosides Antibiotics Drug Revenue by Type (2021-2032)
  3. 10.2.1 China Aminoglycosides Antibiotics Drug Revenue by Type (2021-2026)
  4. 10.2.2 China Aminoglycosides Antibiotics Drug Revenue by Type (2027-2032)
  5. 10.3 China Aminoglycosides Antibiotics Drug Revenue Share by Type (2021-2032)
  6. 10.4 China Aminoglycosides Antibiotics Drug Revenue by Application (2021-2032)
  7. 10.4.1 China Aminoglycosides Antibiotics Drug Revenue by Application (2021-2026)
  8. 10.4.2 China Aminoglycosides Antibiotics Drug Revenue by Application (2027-2032)
  9. 10.5 China Aminoglycosides Antibiotics Drug Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Aminoglycosides Antibiotics Drug Revenue (2021-2032)
  2. 11.2 Asia Aminoglycosides Antibiotics Drug Revenue by Type (2021-2032)
  3. 11.2.1 Asia Aminoglycosides Antibiotics Drug Revenue by Type (2021-2026)
  4. 11.2.2 Asia Aminoglycosides Antibiotics Drug Revenue by Type (2027-2032)
  5. 11.3 Asia Aminoglycosides Antibiotics Drug Revenue Share by Type (2021-2032)
  6. 11.4 Asia Aminoglycosides Antibiotics Drug Revenue by Application (2021-2032)
  7. 11.4.1 Asia Aminoglycosides Antibiotics Drug Revenue by Application (2021-2026)
  8. 11.4.2 Asia Aminoglycosides Antibiotics Drug Revenue by Application (2027-2032)
  9. 11.5 Asia Aminoglycosides Antibiotics Drug Revenue Share by Application (2021-2032)
  10. 11.6 Asia Aminoglycosides Antibiotics Drug Revenue by Country
  11. 11.6.1 Asia Aminoglycosides Antibiotics Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Aminoglycosides Antibiotics Drug Revenue by Country (2021-2026)
  13. 11.6.3 Asia Aminoglycosides Antibiotics Drug Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Aminoglycosides Antibiotics Drug Revenue (2021-2032)
  2. 12.2 SAMEA Aminoglycosides Antibiotics Drug Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Aminoglycosides Antibiotics Drug Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Aminoglycosides Antibiotics Drug Revenue by Type (2027-2032)
  5. 12.3 SAMEA Aminoglycosides Antibiotics Drug Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Aminoglycosides Antibiotics Drug Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Aminoglycosides Antibiotics Drug Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Aminoglycosides Antibiotics Drug Revenue by Application (2027-2032)
  9. 12.5 SAMEA Aminoglycosides Antibiotics Drug Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Aminoglycosides Antibiotics Drug Revenue by Country
  11. 12.6.1 SAMEA Aminoglycosides Antibiotics Drug Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Aminoglycosides Antibiotics Drug Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Aminoglycosides Antibiotics Drug Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst